Evidence map›Paper›PMID 34519913›Full record

Observational studyCardiovascular drugs and therapy2022

Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure.

Michele Correale, Pietro Mazzeo, Adriana Mallardi, Alessandra Leopizzi, Lucia Tricarico, Martino Fortunato, Michele Magnesa, Salvatore Tucci, Pasquale Maiellaro, Giuseppe Pastore and 4 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Dual ETFundamental & clinical pharmacology · 2025
    Article
  5. Observational
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Michele CorrealeOspedali Riuniti University Hospital, Foggia, Italy.
Pietro MazzeoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Adriana MallardiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Alessandra LeopizziDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Lucia TricaricoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Martino FortunatoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Michele MagnesaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Salvatore TucciDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Pasquale MaiellaroDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Giuseppe PastoreDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Olga LamacchiaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Massimo IacovielloDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Matteo Di BiaseDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. natale.brunetti@unifg.it.ORCID 0000-0001-9610-7408
University of Foggia · ITOspedali Riuniti di Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of sodium-glucose-cotransporter-type-2 inhibitors (SGLT2i) was associated in previous studies with an improved vascular function in non-human experimental models. We therefore sought to evaluate possible changes in endothelial function assessed by flow-mediated dilation (FMD) in patients with chronic heart failure (CHF) and type-2 diabetes mellitus (T2DM), switching from other oral hypoglycemic agents to SGLT2i in an observational study.

methodsTwenty-two consecutive outpatients with CHF and T2DM were enrolled after switching to SGLT2i therapy, and compared with 23 consecutive controls from the same registry comparable for principal clinical characteristics. In all patients, endothelial function was assessed by FMD at baseline and after 3 months of follow-up.

resultsThree months of therapy with SGLT2i were associated with a statistically significant improvement in endothelial function (19.0 ± 5.7% vs 8.5 ± 4.1%, p < 0.0001); baseline levels of FMD were comparable between groups (p n.s.). Therapy with SGLT2i was significantly associated to improved FMD levels even at multivariable stepwise regression analysis (p < 0.001).

conclusionsSwitch to SGLT2i in patients with CHF and T2DM was associated in an observational non-randomized study with an improved endothelial function.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsHumansSodium-Glucose Transporter 2 InhibitorsChronic heart failureEndothelial dysfunctionFlow-mediated dilationGliflozinsSGLT2Sodium-glucose-cotransporter-2 inhibitorsType 2 diabetes mellitus

Identifiers

PMID34519913
PMCPMC9652233
OpenAlexW3199192573

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.